Andere Sprachen Luye Pharma Group Ltd.

Aktien

A116Z9

BMG570071099

2186

Verzögert Hong Kong S.E. Andere Börsenplätze 10:08:42 28.06.2024			% 5 Tage	% 1. Jan.
2.7 ^HKD	-0.74%		-4.93%	-27.61%

21.06.	Luye Pharma erhält chinesische Zulassung für die Behandlung der Parkinson-Krankheit	MT
20.06.	Luye Pharma Group Ltd. gibt bekannt, dass das von der Gruppe entwickelte Jinyouping ® (Rotigotin-Mikrosphären zur Injektion, Ly03003) zugelassen worden ist	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Luye Pharma : Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI ...	28.06.
Luye Pharma Secures Chinese Medical Regulatory Approval for Parkinson’s Disease Treatment	21.06.
Luye Pharma Group Ltd. Announces Its Jinyouping ® (Rotigotine Microspheres for Injection, Ly03003) Developed by the Group Has Been Approved	20.06.
Luye Pharma : Jinyouping (Rotigotine Microspheres for Injection) Approved for Marketing in China	20.06.
China Grants Marketing Approval to Luye Pharma's Anti-Schizophrenia Tablets	12.06.
Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China	11.06.
Luye Pharma : Meibirui (Paliperidone Palmitate Injection) Approved for Marketing in China for Treating Schizophrenia	11.06.
Luye Pharma's Japanese Partner Towa Files New Drug Application for Dementia Patch	06.06.
Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	07.03.
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug	04.03.
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610	04.03.
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%	02.02.
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States	01.02.
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List	13.12.
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval	13.12.
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	12.12.
Luye Pharma : Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong	12.12.
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong	12.12.
Luye Pharma Group Ltd. Announces Board Changes	06.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Luye Pharma Group Ltd.

Aktien

A116Z9

BMG570071099

2186

Andere Sprachen

Filter